Markedly elevated CA 19-9 in the pus and the serum of a patient with pyogenic liver abscess [7]

Journal of Clinical Gastroenterology

Volumn 40, Issue 7, 2006, Pages 657-

  Giannaris, Markos ^a   Dourakis, Spyros P ^a   Alexopoulou, Alexandra ^a   Archimandritis, Athanasios J ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; CA 19-9 ANTIGEN; METRONIDAZOLE; PIPERACILLIN PLUS TAZOBACTAM;

AGED; CASE REPORT; COLONOSCOPY; COMPUTER ASSISTED TOMOGRAPHY; ESCHERICHIA COLI; FEMALE; HUMAN; LETTER; LIVER FUNCTION TEST; NONHUMAN; PERCUTANEOUS DRAINAGE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PUSTULAR PSORIASIS; PYOGENIC LIVER ABSCESS; SYMPTOMATOLOGY;

AGED; BILE DUCTS; BIOLOGICAL MARKERS; CA-19-9 ANTIGEN; EPITHELIAL CELLS; FEMALE; HUMANS; LIVER ABSCESS, PYOGENIC; SUPPURATION;

EID: 33747505065     PISSN: 01920790     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004836-200608000-00026     Document Type: Letter

References (6)

1. Ritts RE Jr, Del Villano BC, Go VL, et al. Initial clinical evaluation of an immunoradiometric assay for CA 19-9 using the NCI serum bank. Int J Cancer. 1984;33:339-345.
2. Posner MR, Mayer RJ. The use of serologic tumor markers in gastro- intestinal malignancies. Hematol Oncol Clin North Am. 1994;8:533-553.
3. Pleskow DK, Berger HJ, Gyves J, et al. Evaluation of a serologic marker, CA 19-9, in the diagnosis of pancreatic cancer. Ann Intern Med. 1989;110:704-709.
4. Pfister M, Gottstein B, Kretschmer R, et al. Elevated carbohydrate antigen 19-9 (CA 19-9) in patients with Echinococcus infection. Clin Chem Lab Med. 2001;39:527-530.
5. Kadayifci A, Simsek H, Savas MC, et al. Serum tumor markers in chronic liver disease. Neoplasma. 1996;43:17-21.
6. Yokoyama Y, Yoshida Y, Hayashi T, et al. Increased levels of CA 19-9 in the pus of amebic liver abscess. Am J Gastroenterol. 1993;88:618-619.